

State of Oklahoma SoonerCare

Polivy® (Polatuzumab Vedotin-piiq) Prior Authorization Form

Member Name:	Date of Birth:	Member ID#:
	Drug Informat	ion
Physician billing (HCPCS code:) Start Date (or date of next dose):		
Dose:	Dosing Regimen:_	
	Billing Provider Info	ormation
Provider NPI:	Provider Name:	
Provider Phone:	Provider Fax:	
	Prescriber Inform	nation
Prescriber NPI:	Prescriber Name:	
Prescriber Phone:	Prescriber Fax:	Specialty:
Criteria Criteria		
1. Please indicate the diagnosis and information: □ Diffuse Large B-Cell Lymphoma (DLBCL) A. Is the diagnosis previously untreated DLBCL not otherwise specified or high-grade B-cell lymphoma? Yes No i. If yes, does the member have an International Prognostic Index score of ≥2? Yes No ii. Will polatuzumab vedotin be used in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP)? Yes No B. Is the diagnosis relapsed/refractory DLBCL not otherwise specified or high-grade B-cell lymphoma? Yes No i. Is member a candidate for transplant, or does member have the intention to proceed to hematopoietic stem cell transplant? Yes No □ If diagnosis is not listed above, please indicate diagnosis: For Continued Authorization: 1. Date of last dose: 2. Does member have any evidence of progressive disease while on polatuzumab vedotin? Yes No 3. Has the member experienced adverse drug reactions related to polatuzumab vedotin therapy? Yes No If yes, please specify adverse reactions: Additional Information:		
		Date:
I certify that the indicated tro	eatment is medically necessa	ary and all information is true and correct to

PLEASE PROVIDE THE INFORMATION REQUESTED AND RETURN TO:

University of Oklahoma College of Pharmacy Pharmacy Management Consultants Product Based Prior Authorization Unit

> Fax: 1-800-224-4014 Phone: 1-800-522-0114 Option 4

CONFIDENTIALITY NOTICE

This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.

Pharm – 143 5/3/2024

the best of my knowledge. Failure to complete this form in full will result in processing delays.